Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product ...

Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE ...

A study was conducted to assess the effect of not using postprocedural drains in patients receiving epicardial access on risk for complications.

John Mauceri, an award-winning music conductor, author, and recording artist, is celebrating his return to the stage in ...

Medical pros revisit the 150-year history of coffee enemas to weigh their potential benefits and hidden dangers.

Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu ...

Patients with thyrotoxicosis who developed thyroid storm died at nearly double the rate as those without thyroid storm, ...

Objective Biochemical analysis of pericardial fluid (PF) is commonly performed for the initial ... normal composition of PF in candidates for cardiac surgery. Methods Cohort study with analysis of PF ...